{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T17:30:03Z","timestamp":1780421403309,"version":"3.54.1"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,9,24]],"date-time":"2013-09-24T00:00:00Z","timestamp":1379980800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s12016-013-8388-5","type":"journal-article","created":{"date-parts":[[2013,9,23]],"date-time":"2013-09-23T02:12:44Z","timestamp":1379902364000},"page":"274-288","source":"Crossref","is-referenced-by-count":15,"title":["New Strategies in the Management of Guillain\u2013Barr\u00e9 Syndrome"],"prefix":"10.1007","volume":"47","author":[{"given":"Jinting","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain R.","family":"Simard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Dong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,9,24]]},"reference":[{"key":"8388_CR1","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/cid\/cir074","volume":"52","author":"D Orlikowski","year":"2011","unstructured":"Orlikowski D, Porcher R, Sivadon-Tardy V, Quincampoix JC, Raphael JC, Durand MC et al (2011) Guillain\u2013Barr\u00e9 syndrome following primary cytomegalovirus infection: a prospective cohort study. Clin Infect Dis 52:837\u2013844","journal-title":"Clin Infect Dis"},{"key":"8388_CR2","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.clinph.2012.01.025","volume":"123","author":"A Uncini","year":"2012","unstructured":"Uncini A, Kuwabara S (2012) Electrodiagnostic criteria for Guillain\u2013Barr\u00e9 syndrome: a critical revision and the need for an update. Clin Neurophysiol 123:1487\u20131495","journal-title":"Clin Neurophysiol"},{"key":"8388_CR3","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.amjcard.2009.06.069","volume":"104","author":"S Mukerji","year":"2009","unstructured":"Mukerji S, Aloka F, Farooq MU, Kassab MY, Abela GS (2009) Cardiovascular complications of the Guillain\u2013Barr\u00e9 syndrome. Am J Cardiol 104:1452\u20131455","journal-title":"Am J Cardiol"},{"key":"8388_CR4","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMra1114525","volume":"366","author":"N Yuki","year":"2012","unstructured":"Yuki N, Hartung HP (2012) Guillain\u2013Barr\u00e9 syndrome. N Engl J Med 366:2294\u20132304","journal-title":"N Engl J Med"},{"key":"8388_CR5","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","volume":"363","author":"R Koningsveld van","year":"2004","unstructured":"van Koningsveld R, Schmitz PI, Meche FG, Visser LH, Meulstee J, van Doorn PA (2004) Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain\u2013Barr\u00e9 syndrome: randomised trial. Lancet 363:192\u2013196","journal-title":"Lancet"},{"key":"8388_CR6","doi-asserted-by":"crossref","unstructured":"Plasma Exchange\/Sandoglobulin Guillain\u2013Barr\u00e9 Syndrome Trial Group (1997) Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain\u2013Barr\u00e9 syndrome. Lancet 349:225\u2013230","DOI":"10.1016\/S0140-6736(96)09095-2"},{"key":"8388_CR7","doi-asserted-by":"crossref","unstructured":"Hughes RA, Swan AV, van Doorn PA (2012) Intravenous immunoglobulin for Guillain\u2013Barr\u00e9 syndrome. Cochrane Database Syst Rev 7, CD002063","DOI":"10.1002\/14651858.CD002063.pub5"},{"key":"8388_CR8","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/ana.21816","volume":"66","author":"DR Cornblath","year":"2009","unstructured":"Cornblath DR, Hughes RA (2009) Treatment for Guillain\u2013Barr\u00e9 syndrome. Ann Neurol 66:569\u2013570","journal-title":"Ann Neurol"},{"key":"8388_CR9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/nrneurol.2012.92","volume":"8","author":"RA Hughes","year":"2012","unstructured":"Hughes RA, Lunn MP (2012) Neuromuscular disease: IVIg for neuromuscular disease-effective but expensive. Nat Rev Neurol 8:303\u2013305","journal-title":"Nat Rev Neurol"},{"key":"8388_CR10","doi-asserted-by":"crossref","unstructured":"Raphael JC, Chevret S, Hughes RA, Annane D (2012) Plasma exchange for Guillain\u2013Barr\u00e9 syndrome. Cochrane Database Syst Rev 7, CD001798","DOI":"10.1002\/14651858.CD001798.pub2"},{"key":"8388_CR11","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/jca.21219","volume":"27","author":"K Gwathmey","year":"2012","unstructured":"Gwathmey K, Balogun RA, Burns T (2012) Neurologic indications for therapeutic plasma exchange: 2011 update. J Clin Apher 27:138\u2013145","journal-title":"J Clin Apher"},{"key":"8388_CR12","doi-asserted-by":"crossref","unstructured":"Hughes RA, Swan AV, van Doorn, PA (2010).Corticosteroids for Guillain\u2013Barr\u00e9 syndrome. Cochrane Database Syst Rev, CD001446","DOI":"10.1002\/14651858.CD001446.pub3"},{"key":"8388_CR13","unstructured":"Hughes RA, van Doorn PA (2012) Corticosteroids for Guillain\u2013Barr\u00e9 syndrome. Cochrane Database Syst Rev 8, CD001446"},{"key":"8388_CR14","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0140-6736(05)60466-7","volume":"352","author":"A Creange","year":"1998","unstructured":"Creange A, Lerat H, Meyrignac C, Degos JD, Gherardi RK, Cesaro P (1998) Treatment of Guillain\u2013Barr\u00e9 syndrome with interferon-beta. Lancet 352:368\u2013369","journal-title":"Lancet"},{"key":"8388_CR15","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A (2008) Multiple sclerosis. Lancet 372:1502\u20131517","journal-title":"Lancet"},{"key":"8388_CR16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000050798","volume":"46","author":"B Schaller","year":"2001","unstructured":"Schaller B, Radziwill AJ, Steck AJ (2001) Successful treatment of Guillain\u2013Barr\u00e9 syndrome with combined administration of interferon-beta-1a and intravenous immunoglobulin. Eur Neurol 46:167\u2013168","journal-title":"Eur Neurol"},{"key":"8388_CR17","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1212\/01.WNL.0000092019.53628.88","volume":"61","author":"J Pritchard","year":"2003","unstructured":"Pritchard J, Gray IA, Idrissova ZR, Lecky BR, Sutton IJ, Swan AV et al (2003) A randomized controlled trial of recombinant interferon-beta 1a in Guillain\u2013Barr\u00e9 syndrome. Neurology 61:1282\u20131284","journal-title":"Neurology"},{"key":"8388_CR18","first-page":"1200","volume":"66","author":"M Odaka","year":"2008","unstructured":"Odaka M (2008) CSF filtration and interferon-beta for Guillain\u2013Barr\u00e9 syndrome. Nippon Rinsho 66:1200\u20131204","journal-title":"Nippon Rinsho"},{"key":"8388_CR19","doi-asserted-by":"crossref","unstructured":"Hughes RA, Pritchard J, Hadden RD (2011) Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain\u2013Barr\u00e9 syndrome. Cochrane Database Syst Rev, CD008630.","DOI":"10.1002\/14651858.CD008630.pub2"},{"key":"8388_CR20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jneuroim.2008.03.008","volume":"196","author":"K Mangano","year":"2008","unstructured":"Mangano K, Dati G, Quattrocchi C, Proietti L, Mazzarino C, Di Marco R et al (2008) Preventive and curative effects of cyclophosphamide in an animal model of Guillain\u2013Barr\u00e9 syndrome. J Neuroimmunol 196:107\u2013115","journal-title":"J Neuroimmunol"},{"key":"8388_CR21","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1001\/archneur.1986.00520060066020","volume":"43","author":"I Korn-Lubetzki","year":"1986","unstructured":"Korn-Lubetzki I, Abramsky O (1986) Acute and chronic demyelinating inflammatory polyradiculoneuropathy. Association with autoimmune diseases and lymphocyte response to human neuritogenic protein. Arch Neurol 43:604\u2013608","journal-title":"Arch Neurol"},{"key":"8388_CR22","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1177\/0961203313476358","volume":"22","author":"Y Santiago-Casas","year":"2013","unstructured":"Santiago-Casas Y, Peredo R, Vila L (2013) Efficacy of low-dose intravenous cyclophosphamide in systemic lupus erythematosus presenting with Guillain\u2013Barr\u00e9 syndrome-like acute axonal neuropathies: report of two cases. Lupus 22:324\u2013327","journal-title":"Lupus"},{"key":"8388_CR23","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/ndt\/16.4.840","volume":"16","author":"HW Laarhoven van","year":"2001","unstructured":"van Laarhoven HW, Rooyer FA, van Engelen BG, van Dalen R, Berden JH (2001) Guillain\u2013Barr\u00e9 syndrome as presenting feature in a patient with lupus nephritis, with complete resolution after cyclophosphamide treatment. Nephrol Dial Transplant 16:840\u2013842","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"8388_CR24","doi-asserted-by":"crossref","first-page":"s12","DOI":"10.1177\/096120330501400104","volume":"14","author":"G Zandman-Goddard","year":"2005","unstructured":"Zandman-Goddard G, Shoenfeld Y (2005) Mycophenolate mofetil in animal models of autoimmune disease. Lupus 14(Suppl 1):s12\u2013s16","journal-title":"Lupus"},{"key":"8388_CR25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jneuroim.2008.05.029","volume":"201\u2013202","author":"SP Janssen","year":"2008","unstructured":"Janssen SP, Phernambucq M, Martinez-Martinez P, De Baets MH, Losen M (2008) Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil. J Neuroimmunol 201\u2013202:111\u2013120","journal-title":"J Neuroimmunol"},{"key":"8388_CR26","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/jnnp.2006.102731","volume":"78","author":"MP Garssen","year":"2007","unstructured":"Garssen MP, van Koningsveld R, van Doorn PA, Merkies IS, Scheltens-de Boer M, van Leusden JA et al (2007) Treatment of Guillain\u2013Barr\u00e9 syndrome with mycophenolate mofetil: a pilot study. J Neurol Neurosurg Psychiatry 78:1012\u20131013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8388_CR27","doi-asserted-by":"crossref","unstructured":"Hughes RA, Pritchard J, Hadden RD (2013) Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain\u2013Barr\u00e9 syndrome. Cochrane Database Syst Rev 2, CD008630","DOI":"10.1002\/14651858.CD008630.pub3"},{"key":"8388_CR28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/0961203312469261","volume":"22","author":"GM Daleboudt","year":"2013","unstructured":"Daleboudt GM, Reinders ME, den Hartigh J, Huizinga TW, Rabelink AJ, de Fijter JW et al (2013) Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil. Lupus 22:171\u2013179","journal-title":"Lupus"},{"key":"8388_CR29","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2165\/11635030-000000000-00000","volume":"72","author":"LL Liu","year":"2012","unstructured":"Liu LL, Jiang Y, Wang LN, Yao L, Li ZL (2012) Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials. Drugs 72:1521\u20131533","journal-title":"Drugs"},{"key":"8388_CR30","doi-asserted-by":"crossref","unstructured":"Andrade-Ortega L, Irazoque-Palazuelos F, Munoz-Lopez S, Rosales-Don Pablo VM (2013) Efficacy and tolerability of rituximab in patients with rhupus. Reumatol Clin 9(4):201\u2013205","DOI":"10.1016\/j.reuma.2012.10.010"},{"key":"8388_CR31","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.leukres.2011.01.030","volume":"35","author":"L Laurenti","year":"2011","unstructured":"Laurenti L, De Padua L, Battendieri R, Tarnani M, Sica S, Blasi MA et al (2011) Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: safety and efficacy evaluation. Leuk Res 35:682\u2013684","journal-title":"Leuk Res"},{"key":"8388_CR32","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.autrev.2011.05.011","volume":"11","author":"BC Kieseier","year":"2012","unstructured":"Kieseier BC, Lehmann HC, Meyer Zu Horste G (2012) Autoimmune diseases of the peripheral nervous system. Autoimmun Rev 11:191\u2013195","journal-title":"Autoimmun Rev"},{"key":"8388_CR33","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.autrev.2011.10.013","volume":"11","author":"RF Vollenhoven van","year":"2012","unstructured":"van Vollenhoven RF (2012) Rituximab\u2014shadow, illusion or light? Autoimmun Rev 11:563\u2013567","journal-title":"Autoimmun Rev"},{"key":"8388_CR34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/bmt.2008.81","volume":"42","author":"F Ostronoff","year":"2008","unstructured":"Ostronoff F, Perales MA, Stubblefield MD, Hsu KC (2008) Rituximab-responsive Guillain\u2013Barr\u00e9 syndrome following allogeneic hematopoietic SCT. Bone Marrow Transplant 42:71\u201372","journal-title":"Bone Marrow Transplant"},{"key":"8388_CR35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/aim.2010.003616","volume":"29","author":"JJ Park","year":"2011","unstructured":"Park JJ, Akazawa M, Ahn J, Beckman-Harned S, Lin FC, Lee K et al (2011) Acupuncture sensation during ultrasound guided acupuncture needling. Acupunct Med 29:257\u2013265","journal-title":"Acupunct Med"},{"key":"8388_CR36","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.etp.2009.11.002","volume":"63","author":"Q Yan","year":"2011","unstructured":"Yan Q, Ruan JW, Ding Y, Li WJ, Li Y, Zeng YS (2011) Electro-acupuncture promotes differentiation of mesenchymal stem cells, regeneration of nerve fibers and partial functional recovery after spinal cord injury. Exp Toxicol Pathol 63:151\u2013156","journal-title":"Exp Toxicol Pathol"},{"key":"8388_CR37","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.neures.2011.03.010","volume":"70","author":"SF Huang","year":"2011","unstructured":"Huang SF, Ding Y, Ruan JW, Zhang W, Wu JL, He B et al (2011) An experimental electro-acupuncture study in treatment of the rat demyelinated spinal cord injury induced by ethidium bromide. Neurosci Res 70:294\u2013304","journal-title":"Neurosci Res"},{"key":"8388_CR38","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/1534735407305892","volume":"6","author":"B Kavoussi","year":"2007","unstructured":"Kavoussi B, Ross BE (2007) The neuroimmune basis of anti-inflammatory acupuncture. Integr Cancer Ther 6:251\u2013257","journal-title":"Integr Cancer Ther"},{"key":"8388_CR39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.autneu.2010.03.010","volume":"157","author":"SK Kim","year":"2010","unstructured":"Kim SK, Bae H (2010) Acupuncture and immune modulation. Auton Neurosci 157:38\u201341","journal-title":"Auton Neurosci"},{"key":"8388_CR40","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11726-010-0055-2","volume":"8","author":"W Jing-xi","year":"2010","unstructured":"Jing-xi W (2010) Case report of three patients with Wei-flaccidity syndrome cured by aupuncture-moxibustion therapy. J Acupunct Tuina Sci 8:55\u201357","journal-title":"J Acupunct Tuina Sci"},{"key":"8388_CR41","unstructured":"Zou H (2010) Clinical observation of 38 cases of Guillain\u2013Barr\u00e9 sydrome treated by needle medicine. J Shandong Univ 221\u2013222"},{"key":"8388_CR42","unstructured":"Lu Q, Wang H, Kang B (2010) Observations on the restoring effect of combined acupuncture and medicine on myodynamia in patients with Guillain\u2013Barr\u00e9 syndrome. Shanghai J Acu-Mox 300\u2013302"},{"key":"8388_CR43","unstructured":"Zeng S, Zhong D, Li Y (2008) Progress of acupuncture in the treatment of Guillain\u2013Barr\u00e9 syndrome. Tradit Chin Med 51\u201352"},{"key":"8388_CR44","unstructured":"Wang H, Li M, Xiang B (2006) Clinical progress of Guillain\u2013Barr\u00e9 syndrome by Chinese medicine treatment. Tradit Chin Med Jilin 75\u201376"},{"key":"8388_CR45","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1468-1331.2003.00502_3.x","volume":"10","author":"QD Yang","year":"2003","unstructured":"Yang QD, Long XY, Peng LX, Xu XP, Wang Y, Wu Y et al (2003) Tripterugium wilfordii multiglucoside-treated case of sensory perineuritis. Eur J Neurol 10:188\u2013190","journal-title":"Eur J Neurol"},{"key":"8388_CR46","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s10067-010-1497-0","volume":"29","author":"W Ji","year":"2010","unstructured":"Ji W, Li J, Lin Y, Song YN, Zhang M, Ke Y et al (2010) Report of 12 cases of ankylosing spondylitis patients treated with Tripterygium wilfordii. Clin Rheumatol 29:1067\u20131072","journal-title":"Clin Rheumatol"},{"key":"8388_CR47","doi-asserted-by":"crossref","first-page":"e20751","DOI":"10.1371\/journal.pone.0020751","volume":"6","author":"J Xiong","year":"2011","unstructured":"Xiong J, Wang H, Guo G, Wang S, He L, Chen H et al (2011) Male germ cell apoptosis and epigenetic histone modification induced by Tripterygium wilfordii Hook F. PLoS One 6:e20751","journal-title":"PLoS One"},{"issue":"229\u2013240","key":"8388_CR48","first-page":"W249","volume":"151","author":"R Goldbach-Mansky","year":"2009","unstructured":"Goldbach-Mansky R, Wilson M, Fleischmann R, Olsen N, Silverfield J, Kempf P et al (2009) Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Ann Intern Med 151(229\u2013240):W249\u2013W251","journal-title":"Ann Intern Med"},{"key":"8388_CR49","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.bbrc.2006.05.024","volume":"345","author":"Q Liu","year":"2006","unstructured":"Liu Q, Chen T, Chen G, Li N, Wang J, Ma P et al (2006) Immunosuppressant triptolide inhibits dendritic cell-mediated chemoattraction of neutrophils and T cells through inhibiting Stat3 phosphorylation and NF-kappaB activation. Biochem Biophys Res Commun 345:1122\u20131130","journal-title":"Biochem Biophys Res Commun"},{"key":"8388_CR50","unstructured":"Zhang X, Xia J, Ye H (2000) [Effect of Tripterygium polyglycoside on interleukin-6 in patients with Guillain\u2013Barr\u00e9 syndrome]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 20:332\u2013334"},{"key":"8388_CR51","unstructured":"Zhang X, Xia J, Ye H (2001) Study of serum and CSF IL-6 and siL-2R of Guillain\u2013Barr\u00e9 syndrome patients with Triterygium wilfordii. Chin J Immunol 1:53\u201354"},{"key":"8388_CR52","unstructured":"Xiao B, Shao HY, Xie GJ, Li J, Yang H, Zhou WB et al (2001) Coordinating stimulus molecule in the incidence of nerve of sex of experimental allergy neuritis and the effect of glucoside Tripterygium wilfordii. Stroke and Nervous Diseases 8:67\u201370"},{"key":"8388_CR53","unstructured":"Xu N, Wang Y, Huang G, Wu M, Tang H, Z W (2009) Expression of TLR9 mRNA in experimental allergic neuritis and its dependence on TWP. Sci Tech Rev 8:59\u201363"},{"key":"8388_CR54","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/aps.2012.108","volume":"33","author":"W Tang","year":"2012","unstructured":"Tang W, Zuo JP (2012) Immunosuppressant discovery from Tripterygium wilfordii Hook f: the novel triptolide analog (5R)-5-hydroxytriptolide (LLDT-8). Acta Pharmacol Sin 33:1112\u20131118","journal-title":"Acta Pharmacol Sin"},{"key":"8388_CR55","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrn3379","volume":"14","author":"H Park","year":"2013","unstructured":"Park H, Poo MM (2013) Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci 14:7\u201323","journal-title":"Nat Rev Neurosci"},{"key":"8388_CR56","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.2174\/092986707781745578","volume":"14","author":"O Schulte-Herbruggen","year":"2007","unstructured":"Schulte-Herbruggen O, Braun A, Rochlitzer S, Jockers-Scherubl MC, Hellweg R (2007) Neurotrophic factors\u2014a tool for therapeutic strategies in neurological, neuropsychiatric and neuroimmunological diseases? Curr Med Chem 14:2318\u20132329","journal-title":"Curr Med Chem"},{"key":"8388_CR57","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1073\/pnas.40.10.1014","volume":"40","author":"S Cohen","year":"1954","unstructured":"Cohen S, Levi-Montalcini R, Hamburger V (1954) A nerve growth-stimulating factor isolated from Sarcom as 37 and 180. Proc Natl Acad Sci U S A 40:1014\u20131018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8388_CR58","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/nm1195-1162","volume":"1","author":"R Kramer","year":"1995","unstructured":"Kramer R, Zhang Y, Gehrmann J, Gold R, Thoenen H, Wekerle H (1995) Gene transfer through the blood\u2013nerve barrier: NGF-engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis. Nat Med 1:1162\u20131166","journal-title":"Nat Med"},{"key":"8388_CR59","first-page":"3","volume":"26","author":"H Liu","year":"2007","unstructured":"Liu H, Zhang B, Fang S, Teng J, Lian Y, Xu Y et al (2007) Repair role of mouse nerve growth factor to peripheral nerve in Guillain\u2013Barr\u00e9 syndrome. Clin J New Drugs Clin Rem 26:3","journal-title":"Clin J New Drugs Clin Rem"},{"key":"8388_CR60","first-page":"3","volume":"32","author":"C Peng","year":"2009","unstructured":"Peng C, Shu X, Yang B, Li J (2009) Obsevation on therapeutic effects of IVIG and mNGF cure for children with Guillain\u2013Barr\u00e9 syndrome. Acta Acad Med ZunYi 32:3","journal-title":"Acta Acad Med ZunYi"},{"key":"8388_CR61","first-page":"2","volume":"42","author":"T Chen","year":"2013","unstructured":"Chen T, Guo Q, Yang Y, Shui L (2013) Therapeutic effects of mNGF and IVIG for the children with Guillain\u2013Barr\u00e9 syndrome. Med ChongQing 42:2","journal-title":"Med ChongQing"},{"key":"8388_CR62","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/jnc.12168","volume":"125","author":"J Xiao","year":"2013","unstructured":"Xiao J, Hughes RA, Lim JY, Wong AW, Ivanusic JJ, Ferner AH et al (2013) A small peptide mimetic of brain-derived neurotrophic factor promotes peripheral myelination. J Neurochem 125:386\u2013398","journal-title":"J Neurochem"},{"key":"8388_CR63","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.neuroscience.2012.09.056","volume":"239","author":"M Singh","year":"2013","unstructured":"Singh M, Su C (2013) Progesterone, brain-derived neurotrophic factor and neuroprotection. Neuroscience 239:84\u201391","journal-title":"Neuroscience"},{"key":"8388_CR64","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJMoa0801119","volume":"359","author":"JC Han","year":"2008","unstructured":"Han JC, Liu QR, Jones M, Levinn RL, Menzie CM, Jefferson-George KS et al (2008) Brain-derived neurotrophic factor and obesity in the WAGR syndrome. N Engl J Med 359:918\u2013927","journal-title":"N Engl J Med"},{"key":"8388_CR65","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/0896-6273(92)90213-W","volume":"8","author":"PS DiStefano","year":"1992","unstructured":"DiStefano PS, Friedman B, Radziejewski C, Alexander C, Boland P, Schick CM et al (1992) The neurotrophins BDNF, NT-3, and NGF display distinct patterns of retrograde axonal transport in peripheral and central neurons. Neuron 8:983\u2013993","journal-title":"Neuron"},{"key":"8388_CR66","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1046\/j.1468-1331.2000.00096.x","volume":"7","author":"S Bensa","year":"2000","unstructured":"Bensa S, Hadden RD, Hahn A, Hughes RA, Willison HJ (2000) Randomized controlled trial of brain-derived neurotrophic factor in Guillain\u2013Barr\u00e9 syndrome: a pilot study. Eur J Neurol 7:423\u2013426","journal-title":"Eur J Neurol"},{"key":"8388_CR67","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0165-5728(02)00017-6","volume":"124","author":"PA Felts","year":"2002","unstructured":"Felts PA, Smith KJ, Gregson NA, Hughes RA (2002) Brain-derived neurotrophic factor in experimental autoimmune neuritis. J Neuroimmunol 124:62\u201369","journal-title":"J Neuroimmunol"},{"key":"8388_CR68","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0261-5614(91)90292-K","volume":"10","author":"W Druml","year":"1991","unstructured":"Druml W, Lechner M, Grimm G (1991) Guillain\u2013Barr\u00e9-syndrome (GBS) is a hypercatabolic but not hypermetabolic disease. Clin Nutr 10:57","journal-title":"Clin Nutr"},{"key":"8388_CR69","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/0148607192016005464","volume":"16","author":"RA Roubenoff","year":"1992","unstructured":"Roubenoff RA, Borel CO, Hanley DF (1992) Hypermetabolism and hypercatabolism in Guillain\u2013Barr\u00e9 syndrome. JPEN J Parenter Enter Nutr 16:464\u2013472","journal-title":"JPEN J Parenter Enter Nutr"},{"key":"8388_CR70","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1941875210396379","volume":"1","author":"M Harms","year":"2011","unstructured":"Harms M (2011) Inpatient management of Guillain\u2013Barr\u00e9 syndrome. Neurohospitalist 1:78\u201384","journal-title":"Neurohospitalist"},{"key":"8388_CR71","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.neulet.2010.04.013","volume":"476","author":"Y Leng","year":"2010","unstructured":"Leng Y, Marinova Z, Reis-Fernandes MA, Nau H, Chuang DM (2010) Potent neuroprotective effects of novel structural derivatives of valproic acid: potential roles of HDAC inhibition and HSP70 induction. Neurosci Lett 476:127\u2013132","journal-title":"Neurosci Lett"},{"key":"8388_CR72","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.brainres.2011.03.040","volume":"1396","author":"L Lv","year":"2011","unstructured":"Lv L, Sun Y, Han X, Xu CC, Tang YP, Dong Q (2011) Valproic acid improves outcome after rodent spinal cord injury: potential roles of histone deacetylase inhibition. Brain Res 1396:60\u201368","journal-title":"Brain Res"},{"key":"8388_CR73","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1007\/s00018-008-8521-4","volume":"65","author":"Z Zhang","year":"2008","unstructured":"Zhang Z, Zhang ZY, Fauser U, Schluesener HJ (2008) Valproic acid attenuates inflammation in experimental autoimmune neuritis. Cell Mol Life Sci 65:4055\u20134065","journal-title":"Cell Mol Life Sci"},{"key":"8388_CR74","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1007\/s11064-011-0522-2","volume":"36","author":"C Yi","year":"2011","unstructured":"Yi C, Zhang Z, Wang W, Zug C, Schluesener HJ (2011) Doxycycline attenuates peripheral inflammation in rat experimental autoimmune neuritis. Neurochem Res 36:1984\u20131990","journal-title":"Neurochem Res"},{"key":"8388_CR75","first-page":"S190","volume":"238","author":"T Lin","year":"2005","unstructured":"Lin T (2005) Effective prevention and treatment of experimental autoimmune neuritis with rapamycin. J Neurol Sci 238:S190","journal-title":"J Neurol Sci"},{"key":"8388_CR76","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1007\/s10753-012-9447-4","volume":"35","author":"H Ramkalawan","year":"2012","unstructured":"Ramkalawan H, Wang YZ, Hurbungs A, Yang YF, Tian FF, Zhou WB et al (2012) Pioglitazone, PPARgamma agonist, attenuates experimental autoimmune neuritis. Inflammation 35:1338\u20131347","journal-title":"Inflammation"},{"key":"8388_CR77","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jneuroim.2006.11.027","volume":"183","author":"JM Taylor","year":"2007","unstructured":"Taylor JM, Pollard JD (2007) Soluble TNFR1 inhibits the development of experimental autoimmune neuritis by modulating blood\u2013nerve-barrier permeability and inflammation. J Neuroimmunol 183:118\u2013124","journal-title":"J Neuroimmunol"},{"key":"8388_CR78","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jneuroim.2008.11.011","volume":"207","author":"XD Tan","year":"2009","unstructured":"Tan XD, Dou YC, Shi CW, Duan RS, Sun RP (2009) Administration of dehydroepiandrosterone ameliorates experimental autoimmune neuritis in Lewis rats. J Neuroimmunol 207:39\u201344","journal-title":"J Neuroimmunol"},{"key":"8388_CR79","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.toxicon.2006.09.028","volume":"49","author":"FR Castro","year":"2007","unstructured":"Castro FR, Farias AS, Proenca PL, de La Hoz C, Langone F, Oliveira EC et al (2007) The effect of treatment with crotapotin on the evolution of experimental autoimmune neuritis induced in Lewis rats. Toxicon 49:299\u2013305","journal-title":"Toxicon"},{"key":"8388_CR80","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.neuroscience.2010.04.074","volume":"169","author":"ZY Zhang","year":"2010","unstructured":"Zhang ZY, Zhang Z, Schluesener HJ (2010) MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis. Neuroscience 169:370\u2013377","journal-title":"Neuroscience"},{"key":"8388_CR81","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/mus.10019","volume":"25","author":"K Miyamoto","year":"2002","unstructured":"Miyamoto K, Oka N, Kawasaki T, Miyake S, Yamamura T, Akiguchi I (2002) New cyclooxygenase-2 inhibitors for treatment of experimental autoimmune neuritis. Muscle Nerve 25:280\u2013282","journal-title":"Muscle Nerve"},{"key":"8388_CR82","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.4049\/jimmunol.0901088","volume":"183","author":"Z Zhang","year":"2009","unstructured":"Zhang Z, Zhang ZY, Schluesener HJ (2009) Compound A, a plant origin ligand of glucocorticoid receptors, increases regulatory T cells and M2 macrophages to attenuate experimental autoimmune neuritis with reduced side effects. J Immunol 183:3081\u20133091","journal-title":"J Immunol"},{"key":"8388_CR83","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pneurobio.2009.02.002","volume":"88","author":"PJ Most van der","year":"2009","unstructured":"van der Most PJ, Dolga AM, Nijholt IM, Luiten PG, Eisel UL (2009) Statins: mechanisms of neuroprotection. Prog Neurobiol 88:64\u201375","journal-title":"Prog Neurobiol"},{"key":"8388_CR84","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/MOL.0b013e3283453e41","volume":"22","author":"DX Bu","year":"2011","unstructured":"Bu DX, Griffin G, Lichtman AH (2011) Mechanisms for the anti-inflammatory effects of statins. Curr Opin Lipidol 22:165\u2013170","journal-title":"Curr Opin Lipidol"},{"key":"8388_CR85","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejim.2007.05.010","volume":"19","author":"L Castilla Guerra","year":"2008","unstructured":"Castilla Guerra L, del Carmen Fernandez Moreno M, Lopez Chozas JM, Jimenez Hernandez MD (2008) Statins in stroke prevention: what an internist should know. Eur J Intern Med 19:8\u201314","journal-title":"Eur J Intern Med"},{"key":"8388_CR86","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11883-008-0003-5","volume":"10","author":"JD Orr","year":"2008","unstructured":"Orr JD (2008) Statins in the spectrum of neurologic disease. Curr Atheroscler Rep 10:11\u201318","journal-title":"Curr Atheroscler Rep"},{"key":"8388_CR87","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/j.1471-4159.2006.04309.x","volume":"100","author":"JP Sarkey","year":"2007","unstructured":"Sarkey JP, Richards MP, Stubbs EB Jr (2007) Lovastatin attenuates nerve injury in an animal model of Guillain\u2013Barr\u00e9 syndrome. J Neurochem 100:1265\u20131277","journal-title":"J Neurochem"},{"key":"8388_CR88","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.cellimm.2011.08.015","volume":"271","author":"XL Li","year":"2011","unstructured":"Li XL, Dou YC, Liu Y, Shi CW, Cao LL, Zhang XQ et al (2011) Atorvastatin ameliorates experimental autoimmune neuritis by decreased Th1\/Th17 cytokines and up-regulated T regulatory cells. Cell Immunol 271:455\u2013461","journal-title":"Cell Immunol"},{"key":"8388_CR89","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/glia.20202","volume":"51","author":"X Li","year":"2005","unstructured":"Li X, Gonias SL, Campana WM (2005) Schwann cells express erythropoietin receptor and represent a major target for Epo in peripheral nerve injury. Glia 51:254\u2013265","journal-title":"Glia"},{"key":"8388_CR90","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/1756285611434926","volume":"5","author":"N Subiros","year":"2012","unstructured":"Subiros N, Del Barco DG, Coro-Antich RM (2012) Erythropoietin: still on the neuroprotection road. Ther Adv Neurol Disord 5:161\u2013173","journal-title":"Ther Adv Neurol Disord"},{"key":"8388_CR91","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1161\/STROKEAHA.110.592394","volume":"42","author":"M Fisher","year":"2011","unstructured":"Fisher M (2011) New approaches to neuroprotective drug development. Stroke 42:S24\u2013S27","journal-title":"Stroke"},{"key":"8388_CR92","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1093\/brain\/awm203","volume":"130","author":"H Ehrenreich","year":"2007","unstructured":"Ehrenreich H, Fischer B, Norra C, Schellenberger F, Stender N, Stiefel M et al (2007) Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 130:2577\u20132588","journal-title":"Brain"},{"key":"8388_CR93","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.brainres.2010.03.072","volume":"1333","author":"M Ahn","year":"2010","unstructured":"Ahn M, Moon C, Jeong C, Matsumoto Y, Koh CS, Shin T (2010) Upregulation of erythropoietin in rat peripheral nervous system with experimental autoimmune neuritis. Brain Res 1333:82\u201390","journal-title":"Brain Res"},{"key":"8388_CR94","doi-asserted-by":"crossref","first-page":"e26280","DOI":"10.1371\/journal.pone.0026280","volume":"6","author":"AK Mausberg","year":"2011","unstructured":"Mausberg AK, Meyer Zu Horste G, Dehmel T, Stettner M, Lehmann HC, Sheikh KA et al (2011) Erythropoietin ameliorates rat experimental autoimmune neuritis by inducing transforming growth factor-beta in macrophages. PLoS One 6:e26280","journal-title":"PLoS One"},{"key":"8388_CR95","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1741-7015-10-24","volume":"10","author":"M Bowerman","year":"2012","unstructured":"Bowerman M, Murray LM, Boyer JG, Anderson CL, Kothary R (2012) Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy. BMC Med 10:24","journal-title":"BMC Med"},{"key":"8388_CR96","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.bone.2012.12.050","volume":"53","author":"S Ikemura","year":"2013","unstructured":"Ikemura S, Yamamoto T, Motomura G, Yamaguchi R, Zhao G, Iwasaki K et al (2013) Preventive effects of the anti-vasospasm agent via the regulation of the Rho-kinase pathway on the development of steroid-induced osteonecrosis in rabbits. Bone 53:329\u2013335","journal-title":"Bone"},{"key":"8388_CR97","first-page":"273","volume":"238","author":"A Pineda","year":"2005","unstructured":"Pineda A, Kira j, Minohara M (2005) The effect of rho-kinase inhibitor fasudil in the clinical course of EAN (experimental autoimmune neuritis). J Neurol Sci 238:273","journal-title":"J Neurol Sci"},{"key":"8388_CR98","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jns.2011.03.031","volume":"306","author":"AA Pineda","year":"2011","unstructured":"Pineda AA, Minohara M, Kawamura N, Matsushita T, Yamasaki R, Sun X et al (2011) Preventive and therapeutic effects of the selective rho-kinase inhibitor fasudil on experimental autoimmune neuritis. J Neurol Sci 306:115\u2013120","journal-title":"J Neurol Sci"},{"key":"8388_CR99","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jneuroim.2009.09.010","volume":"216","author":"ZY Zhang","year":"2009","unstructured":"Zhang ZY, Zhang Z, Zug C, Nuesslein-Hildesheim B, Leppert D, Schluesener HJ (2009) AUY954, a selective S1P(1) modulator, prevents experimental autoimmune neuritis. J Neuroimmunol 216:59\u201365","journal-title":"J Neuroimmunol"},{"key":"8388_CR100","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2990.2009.01016.x","volume":"35","author":"ZY Zhang","year":"2009","unstructured":"Zhang ZY, Zhang Z, Schluesener HJ (2009) FTY720 attenuates lesional interleukin-17(+) cell accumulation in rat experimental autoimmune neuritis. Neuropathol Appl Neurobiol 35:487\u2013495","journal-title":"Neuropathol Appl Neurobiol"},{"key":"8388_CR101","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.expneurol.2007.12.025","volume":"210","author":"Z Zhang","year":"2008","unstructured":"Zhang Z, Zhang ZY, Fauser U, Schluesener HJ (2008) FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves. Exp Neurol 210:681\u2013690","journal-title":"Exp Neurol"},{"key":"8388_CR102","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/brain\/124.9.1791","volume":"124","author":"T Korn","year":"2001","unstructured":"Korn T, Toyka K, Hartung HP, Jung S (2001) Suppression of experimental autoimmune neuritis by leflunomide. Brain 124:1791\u20131802","journal-title":"Brain"},{"key":"8388_CR103","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0028-3908(02)00015-1","volume":"42","author":"LP Zou","year":"2002","unstructured":"Zou LP, Abbas N, Volkmann I, Nennesmo I, Levi M, Wahren B et al (2002) Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1\/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology 42:731\u2013739","journal-title":"Neuropharmacology"},{"key":"8388_CR104","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jneuroim.2005.07.008","volume":"168","author":"M Kafri","year":"2005","unstructured":"Kafri M, Kloog Y, Korczyn AD, Ferdman-Aronovich R, Drory V, Katzav A et al (2005) Inhibition of Ras attenuates the course of experimental autoimmune neuritis. J Neuroimmunol 168:46\u201355","journal-title":"J Neuroimmunol"},{"key":"8388_CR105","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.expneurol.2011.04.016","volume":"230","author":"HL Zhang","year":"2011","unstructured":"Zhang HL, Mao XJ, Zhang XM, Li HF, Zheng XY, Adem A et al (2011) APOE epsilon3 attenuates experimental autoimmune neuritis by modulating T cell, macrophage and Schwann cell functions. Exp Neurol 230:197\u2013206","journal-title":"Exp Neurol"},{"key":"8388_CR106","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0028-3908(99)00144-6","volume":"39","author":"LP Zou","year":"2000","unstructured":"Zou LP, Deretzi G, Pelidou SH, Levi M, Wahren B, Quiding C et al (2000) Rolipram suppresses experimental autoimmune neuritis and prevents relapses in Lewis rats. Neuropharmacology 39:324\u2013333","journal-title":"Neuropharmacology"},{"key":"8388_CR107","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0165-2478(98)00070-4","volume":"63","author":"T Karpati","year":"1998","unstructured":"Karpati T, Karussis D, Abramsky O, Mizrahi-Koll R, Arbell I, Ovadia H (1998) Inhibition of experimental autoimmune neuritis by the immunomodulator linomide. Immunol Lett 63:141\u2013145","journal-title":"Immunol Lett"},{"key":"8388_CR108","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12016-010-8246-7","volume":"42","author":"R Aronovich","year":"2012","unstructured":"Aronovich R, Katzav A, Chapman J (2012) The strategies used for treatment of experimental autoimmune neuritis (EAN): a beneficial effect of glatiramer acetate administered intraperitoneally. Clin Rev Allergy Immunol 42:181\u2013188","journal-title":"Clin Rev Allergy Immunol"},{"key":"8388_CR109","doi-asserted-by":"crossref","first-page":"e4643","DOI":"10.1371\/journal.pone.0004643","volume":"4","author":"T Gogishvili","year":"2009","unstructured":"Gogishvili T, Langenhorst D, Luhder F, Elias F, Elflein K, Dennehy KM et al (2009) Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice. PLoS One 4:e4643","journal-title":"PLoS One"},{"key":"8388_CR110","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0165-5728(03)00182-6","volume":"140","author":"J Schmidt","year":"2003","unstructured":"Schmidt J, Elflein K, Stienekemeier M, Rodriguez-Palmero M, Schneider C, Toyka KV et al (2003) Treatment and prevention of experimental autoimmune neuritis with superagonistic CD28-specific monoclonal antibodies. J Neuroimmunol 140:143\u2013152","journal-title":"J Neuroimmunol"},{"key":"8388_CR111","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0165-5728(00)00460-4","volume":"114","author":"S Jander","year":"2001","unstructured":"Jander S, Stoll G (2001) Interleukin-18 is induced in acute inflammatory demyelinating polyneuropathy. J Neuroimmunol 114:253\u2013258","journal-title":"J Neuroimmunol"},{"key":"8388_CR112","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/jnen\/61.7.614","volume":"61","author":"S Yu","year":"2002","unstructured":"Yu S, Chen Z, Mix E, Zhu SW, Winblad B, Ljunggren HG et al (2002) Neutralizing antibodies to IL-18 ameliorate experimental autoimmune neuritis by counter-regulation of autoreactive Th1 responses to peripheral myelin antigen. J Neuropathol Exp Neurol 61:614\u2013622","journal-title":"J Neuropathol Exp Neurol"},{"key":"8388_CR113","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1172\/JCI59110","volume":"122","author":"SN Fewou","year":"2012","unstructured":"Fewou SN, Rupp A, Nickolay LE, Carrick K, Greenshields KN, Pediani J et al (2012) Anti-ganglioside antibody internalization attenuates motor nerve terminal injury in a mouse model of acute motor axonal neuropathy. J Clin Invest 122:1037\u20131051","journal-title":"J Clin Invest"},{"key":"8388_CR114","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awm316","volume":"131","author":"SK Halstead","year":"2008","unstructured":"Halstead SK, Zitman FM, Humphreys PD, Greenshields K, Verschuuren JJ, Jacobs BC et al (2008) Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 131:1197\u20131208","journal-title":"Brain"},{"key":"8388_CR115","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/jnr.22330","volume":"88","author":"S Usuki","year":"2010","unstructured":"Usuki S, Taguchi K, Thompson SA, Chapman PB, Yu RK (2010) Novel anti-idiotype antibody therapy for lipooligosaccharide-induced experimental autoimmune neuritis: use relevant to Guillain\u2013Barr\u00e9 syndrome. J Neurosci Res 88:1651\u20131663","journal-title":"J Neurosci Res"},{"key":"8388_CR116","doi-asserted-by":"crossref","first-page":"13872","DOI":"10.1073\/pnas.241504598","volume":"98","author":"M Stienekemeier","year":"2001","unstructured":"Stienekemeier M, Falk K, Rotzschke O, Weishaupt A, Schneider C, Toyka KV et al (2001) Vaccination, prevention, and treatment of experimental autoimmune neuritis (EAN) by an oligomerized T cell epitope. Proc Natl Acad Sci U S A 98:13872\u201313877","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8388_CR117","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0165-5728(98)00022-8","volume":"85","author":"LP Zou","year":"1998","unstructured":"Zou LP, Zhu J, Deng GM, Levi M, Wahren B, Diab A et al (1998) Treatment with P2 protein peptide 57\u201381 by nasal route is effective in Lewis rat experimental autoimmune neuritis. J Neuroimmunol 85:137\u2013145","journal-title":"J Neuroimmunol"},{"key":"8388_CR118","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0165-5728(98)00232-X","volume":"94","author":"LP Zou","year":"1999","unstructured":"Zou LP, Ma DH, Levi M, Wahren B, Wei L, Mix E et al (1999) Antigen-specific immunosuppression: nasal tolerance to P0 protein peptides for the prevention and treatment of experimental autoimmune neuritis in Lewis rats. J Neuroimmunol 94:109\u2013121","journal-title":"J Neuroimmunol"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-013-8388-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-013-8388-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-013-8388-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T01:34:22Z","timestamp":1715996062000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-013-8388-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,24]]},"references-count":118,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["8388"],"URL":"https:\/\/doi.org\/10.1007\/s12016-013-8388-5","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,24]]}}}